News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ferring Pharmaceuticals Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the First European Congress on Intrapartum Care



5/28/2013 11:30:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

AMSTERDAM--(BUSINESS WIRE)--Data from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated that use of a controlled release misoprostol vaginal insert significantly reduced time to vaginal delivery compared to a dinoprostone vaginal insert.1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES